CD47xCD19 bispecific antibody triggers recruitment and activation of innate immune effector cells in a B-cell lymphoma xenograft model
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2162-3619
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
CD47xCD19 bispecific antibody triggers recruitment and activation of innate immune effector cells in a B-cell lymphoma xenograft model ; volume:11 ; number:1 ; day:10 ; month:5 ; year:2022 ; pages:1-13 ; date:12.2022
Experimental hematology & oncology ; 11, Heft 1 (10.5.2022), 1-13, 12.2022
- Urheber
-
Chauchet, Xavier
Cons, Laura
Chatel, Laurence
Daubeuf, Bruno
Didelot, Gérard
Moine, Valéry
Chollet, Didier
Malinge, Pauline
Pontini, Guillemette
Masternak, Krzysztof
Ferlin, Walter
Buatois, Vanessa
Shang, Limin
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s40164-022-00279-w
- URN
-
urn:nbn:de:101:1-2022071619212133364326
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:19 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Chauchet, Xavier
- Cons, Laura
- Chatel, Laurence
- Daubeuf, Bruno
- Didelot, Gérard
- Moine, Valéry
- Chollet, Didier
- Malinge, Pauline
- Pontini, Guillemette
- Masternak, Krzysztof
- Ferlin, Walter
- Buatois, Vanessa
- Shang, Limin
- SpringerLink (Online service)
Ähnliche Objekte (12)
Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies
Polyclonal tumor-specific activation of cytotoxic effector cells by bispecific antibody constructs
T-cell surveillance of therapy-induced senescent lymphoma cells in the presence of anti-CD19/CD20 × CD3 bispecific antibodies
A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia
Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
Bispecific CAR-T cells targeting CD19/20 in patients with relapsed or refractory B cell non-Hodgkin lymphoma: a phase I/II trial
Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial
Correction to: Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
Bi-specific Aptamers mediating Tumour Cell Lysis
CD19-immunoPET for noninvasive visualization of CD19 expression in B-cell lymphoma patients
Effector T cells against cancer
T cell‐dependent bispecific antibodies alter organ‐specific endothelial cell–T cell interaction
Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies
Polyclonal tumor-specific activation of cytotoxic effector cells by bispecific antibody constructs
T-cell surveillance of therapy-induced senescent lymphoma cells in the presence of anti-CD19/CD20 × CD3 bispecific antibodies
A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia
Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
Bispecific CAR-T cells targeting CD19/20 in patients with relapsed or refractory B cell non-Hodgkin lymphoma: a phase I/II trial
Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial
Correction to: Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
Bi-specific Aptamers mediating Tumour Cell Lysis
CD19-immunoPET for noninvasive visualization of CD19 expression in B-cell lymphoma patients
Effector T cells against cancer
T cell‐dependent bispecific antibodies alter organ‐specific endothelial cell–T cell interaction
Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies
Polyclonal tumor-specific activation of cytotoxic effector cells by bispecific antibody constructs
T-cell surveillance of therapy-induced senescent lymphoma cells in the presence of anti-CD19/CD20 × CD3 bispecific antibodies
A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia
Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
Bispecific CAR-T cells targeting CD19/20 in patients with relapsed or refractory B cell non-Hodgkin lymphoma: a phase I/II trial
Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial
Correction to: Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
Bi-specific Aptamers mediating Tumour Cell Lysis
CD19-immunoPET for noninvasive visualization of CD19 expression in B-cell lymphoma patients
Effector T cells against cancer